Actualités Transgene SA - TNG | Actions Euronext

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025 2024 Half-Year Results and Business...

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

2024 Half-Year Results and Business Update Lead program TG4050 (individualized immunotherapy): – First signs of...

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024 TRANSGENE (Paris: TNG) today announced that it has made available to...

Mise à disposition du Rapport Financier Semestriel au 30 juin 2024

Mise à disposition du Rapport Financier Semestriel au 30 juin 2024 TRANSGENE (Paris : TNG) annonce avoir mis à la disposition du public et déposé...

Transgene prévoit d’importants résultats cliniques d’ici fin 2024 et confirme sa visibilité financière jusqu’au 4ème trimestre 2025

Transgene prévoit d’importants résultats cliniques d’ici fin 2024 et confirme sa visibilité financière jusqu’au 4ème trimestre 2025 Résultats...

2024 Half-Year Financial Report

2024 Half-Year Financial Report 2024 Half Year Financial Report Attachment TRANSGENE_HALF-YEAR-FINANCIAL-REPORT-2024_EN

Rapport Semestriel 2024

Rapport Semestriel 2024 Rapport Semestriel 2024 Pièce jointe TRANSGENE_RAPPORT-FINANCIER-SEMESTRIEL-2024_FR

Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l’étude en cours de Phase I/IIa dans les tumeurs solides résistantes

Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l’étude en cours de Phase I/IIa dans les...

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed...

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Transgene SA (TNG)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

TNG Actualités

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024

Mise à disposition du Rapport Financier Semestriel au 30 juin 2024

Transgene prévoit d’importants résultats cliniques d’ici fin 2024 et confirme sa visibilité financière jusqu’au 4ème trimestre 2025

2024 Half-Year Financial Report

Rapport Semestriel 2024

Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l’étude en cours de Phase I/IIa dans les tumeurs solides résistantes

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Transgene nomme deux experts en oncologie pour conduire sa prochaine phase d'innovation

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Transgene SA (TNG) Actualités

Transgene SA (TNG)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

TNG Actualités

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024

Mise à disposition du Rapport Financier Semestriel au 30 juin 2024

Transgene prévoit d’importants résultats cliniques d’ici fin 2024 et confirme sa visibilité financière jusqu’au 4ème trimestre 2025

2024 Half-Year Financial Report

Rapport Semestriel 2024

Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l’étude en cours de Phase I/IIa dans les tumeurs solides résistantes

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Transgene nomme deux experts en oncologie pour conduire sa prochaine phase d'innovation

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application